Literature DB >> 10081850

Is everything all right if nothing seems wrong? A simple method of assessing the diagnostic value of endoscopic procedures when a gold standard is absent.

S Schneeweiss1, M Kriegmair, H Stepp.   

Abstract

PURPOSE: We demonstrate a simple yet comprehensive method to evaluate the sensitivity of endoscopic procedures when no gold standard is available.
MATERIALS AND METHODS: In 208 consecutive patients with superficial bladder cancer 328 endoscopies were performed to compare the sensitivity of white light and 5-aminolevulinic acid induced fluorescence endoscopy. Both procedures were performed during the same session.
RESULTS: The maximum interval of observable sensitivity for 5-aminolevulinic acid induced fluorescence endoscopy ranged between 78 and 97.5%, and the best estimate for sensitivity based on realistic assumptions was 93.4% (95% confidence intervals 90 to 97.3). The best sensitivity estimate for white light endoscopy was 46.7% (95% confidence intervals 39.4 to 54.3, maximum range 47.2 to 53%).
CONCLUSIONS: This method to determine the maximum possible range of sensitivity estimates for endoscopic procedures without a gold standard is easily applied. Depending on the assumptions a range of reasonable scenarios can be constructed and the corresponding sensitivities can be reported. This approach gives fast and valid results, and could further indicate the diagnostic superiority of 5-aminolevulinic acid induced fluorescence compared to white light endoscopy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10081850

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  9 in total

1.  Hypermethylated SFRP1, but none of other nine genes "informative" for western countries, is valuable for bladder cancer detection in Mainland China.

Authors:  Jinfeng Sun; Zhou Chen; Tongyu Zhu; Jian Yu; Kelong Ma; Hongyu Zhang; Yinghua He; Xiaoying Luo; Jingde Zhu
Journal:  J Cancer Res Clin Oncol       Date:  2009-06-30       Impact factor: 4.553

2.  Multicenter evaluation of the role of UroVysion FISH assay in surveillance of patients with bladder cancer: does FISH positivity anticipate recurrence?

Authors:  Casey Seideman; Daniel Canter; Philip Kim; Billy Cordon; Alon Weizer; Irma Oliva; Jianyu Rao; Brant A Inman; Michael Posch; Harry Herr; Yair Lotan
Journal:  World J Urol       Date:  2014-11-25       Impact factor: 4.226

3.  Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guérin.

Authors:  Roger Li; Debasish Sundi; Jingsong Zhang; Youngchul Kim; Richard J Sylvester; Philippe E Spiess; Michael A Poch; Wade J Sexton; Peter C Black; James M McKiernan; Gary D Steinberg; Ashish M Kamat; Scott M Gilbert
Journal:  Eur Urol       Date:  2020-03-04       Impact factor: 20.096

4.  Early diagnosis of bladder cancer through the detection of urinary tyrosine-phosphorylated proteins.

Authors:  A Khadjavi; F Mannu; P Destefanis; C Sacerdote; A Battaglia; M Allasia; D Fontana; B Frea; S Polidoro; G Fiorito; G Matullo; A Pantaleo; A Notarpietro; M Prato; F Castagno; P Vineis; P Gontero; G Giribaldi; F Turrini
Journal:  Br J Cancer       Date:  2015-06-30       Impact factor: 7.640

5.  Urinary mRNA biomarker panel for the detection of urothelial carcinoma.

Authors:  Virginia Urquidi; Mandy Netherton; Evan Gomes-Giacoia; Daniel Serie; Jeanette Eckel-Passow; Charles J Rosser; Steve Goodison
Journal:  Oncotarget       Date:  2016-06-21

Review 6.  Review of the Clinical Approaches to the Use of Urine-based Tumor Markers in Bladder Cancer.

Authors:  Timothy Clinton; Yair Lotan
Journal:  Rambam Maimonides Med J       Date:  2017-10-16

7.  Nuclear Matrix Protein 22 in Voided Urine Cytology Efficacy in Risk Stratification for Carcinoma of Bladder.

Authors:  Monica Sankhwar; Rajender Singh; Satya Narayan Sankhwar; Madhu Mati Goel; Amita Jain; Pushp Lata Sankhwar
Journal:  World J Oncol       Date:  2013-07-15

Review 8.  Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA - update 2018.

Authors:  Yair Lotan; Trinity J Bivalacqua; Tracy Downs; William Huang; Jeffrey Jones; Ashish M Kamat; Badrinath Konety; Per-Uno Malmström; James McKiernan; Michael O'Donnell; Sanjay Patel; Kamal Pohar; Matthew Resnick; Alexander Sankin; Angela Smith; Gary Steinberg; Edouard Trabulsi; Michael Woods; Siamak Daneshmand
Journal:  Nat Rev Urol       Date:  2019-06       Impact factor: 14.432

9.  Bladder cancer diagnosis and identification of clinically significant disease by combined urinary detection of Mcm5 and nuclear matrix protein 22.

Authors:  John D Kelly; Tim J Dudderidge; Alex Wollenschlaeger; Odu Okoturo; Keith Burling; Fiona Tulloch; Ian Halsall; Teresa Prevost; Andrew Toby Prevost; Joana C Vasconcelos; Wendy Robson; Hing Y Leung; Nikhil Vasdev; Robert S Pickard; Gareth H Williams; Kai Stoeber
Journal:  PLoS One       Date:  2012-07-09       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.